Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3107 Target Snapshot

Fibroblast growth factor 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
150Compounds
35Assays
0Approved Drugs
149.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Fibroblast growth factor 2 shows late clinical disease relevance led by hepatocellular carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P09038. Start with hepatocellular carcinoma, then reuse UniProt P09038 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hepatocellular carcinoma, then reuse UniProt P09038 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
hepatocellular carcinoma

Fibroblast growth factor 2 shows late clinical disease relevance led by hepatocellular carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with hepatocellular carcinoma because it currently carries late clinical support. Linked drugs include MUPARFOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor 2 as ChEMBL target CHEMBL3107, mapped to UniProt P09038. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fibroblast growth factor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3107
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P09038
Fibroblast growth factor 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Fibroblast growth factor 2 is the right protein anchor across sources, using UniProt P09038 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hepatocellular carcinoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameFibroblast growth factor 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP09038
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelFibroblast growth factor 2
UniProt AccessionP09038
Component TypeProtein
Sequence Length288 aa

Fibroblast growth factor 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Fibroblast growth factor 2, mapped to UniProt P09038. Sequence length is 288 aa.

Mapped IDP09038
Review nameFibroblast growth factor 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Fibroblast growth factor 2 shows late clinical disease relevance led by hepatocellular carcinoma. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
hepatocellular carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase II
lung cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase II
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase II
prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase I
cutaneous melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Clinical signal Phase I
melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hepatocellular carcinoma because it currently carries late clinical support. Linked drugs include MUPARFOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehepatocellular carcinoma
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC5016.0
KD133.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3686884 8.35 IC50 4.5 Clinical
CHEMBL3559508 8.33 Kd 4.7 Preclinical
CHEMBL3397498 8.31 Kd 4.9 Preclinical
CHEMBL3686883 8.29 IC50 5.1 Preclinical
CHEMBL3409457 8.28 Kd 5.2 Preclinical
CHEMBL3409454 8.25 Kd 5.6 Preclinical
CHEMBL3686864 8.19 IC50 6.4 Preclinical
CHEMBL3409455 8.09 Kd 8.2 Preclinical
CHEMBL3409453 7.8 Kd 16.0 Preclinical
CHEMBL3397488 7.8 Kd 16.0 Preclinical
Distribution

pChEMBL Value Distribution

5
5.0
6
5.5
13
6.0
12
6.5
21
7.0
5
7.5
8
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

35
Total Assays
125
Tested Compounds
1
Assay Types
Binding — 35 assays, 125 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 30 122 6.6
cell-based format 5 3 4.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine